Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Qatar Investment Authority investment in Reliance Industries’ Reliance Retail Ventures
We are advising Reliance on the transaction
Abcam $5.7 billion acquisition by Danaher
We advised financial advisers to Abcam on the transaction
Chindata Group going-private transaction
We are advising APG on the transaction
SSI Strategy acquisition of NDA Group
We advised SSI Strategy on the acquisition
MSCI $697 million acquisition of Burgiss Group
We are advising MSCI on the acquisition
Arco Platform $1.5 billion going-private transaction
We are advising Arco Platform on the transaction
Lorom merger with In-Tech
We advised Cornell Capital and Lorom on the transaction
Sale of majority stake in Engage PEO to Kohlberg & Company
We advised Engage PEO and Lightyear Capital on the transaction
Allegro MicroSystems $420 million acquisition of Crocus Technology
We are advising Allegro MicroSystems on the acquisition
Roper Technologies $1.25 billion acquisition of Syntellis Performance Solutions
We advised Roper Technologies on the acquisition